Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02406742
Title A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL (ENHANCE)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celgene Corporation
Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Obinutuzumab

Rituximab

Ibrutinib

CC-122

Age Groups: adult
Covered Countries USA | ITA | ESP | DEU | AUT


No variant requirements are available.